Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05348993 · ClinicalTrials.gov registry record · Phase 2
Single or Repeat Dose of G03-52-01 in Adult Subjects
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 622
- Enrollment target
NCT05348993 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 622 participants.
The verdict
NCT05348993, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 622 participants
- Enrollment target
Study Summary
A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
Interventions
- DRUG Placebo
- DRUG G03-52-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05348993
The ClinicalTrials.gov registry entry for NCT05348993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05348993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05348993 about?
NCT05348993 is a clinical study titled "Single or Repeat Dose of G03-52-01 in Adult Subjects". A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
What is the current status of trial NCT05348993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 622 participants. The study started on 2022-06-15. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT05348993?
The interventions under investigation include: Placebo (DRUG), G03-52-01 (DRUG).
Who is sponsoring clinical trial NCT05348993?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.